Mode
Text Size
Log in / Sign up
Phase 2 N=70 Randomized Triple-blind Treatment

RNS® System Feasibility Study

Epilepsy

Enrolled (actual)
70
Serious AEs
44.6%
Results posted
Dec 2013
Primary outcome: Primary: Acute SAE Rate — 6.2 percentage of participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
RNS® System implantation (Procedure); RNS® System responsive stimulation (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
NeuroPace
Primary completion
May 2006

Outcome Measures

OutcomeResultp-value
PRIMARY
Acute SAE Rate
6.2
PRIMARY
Short-term Chronic SAE Rate
9.2
PRIMARY
Responder Rate
24

Summary

The RNS® System is intended to treat patients with medically refractory (hard to treat) epilepsy. The RNS® System Feasibility study is designed to demonstrate safety and evidence of effectiveness of the RNS® System to support the commencement of a pivotal clinical investigation.

Eligibility Criteria

Inclusion Criteria

  • Subject has simple partial seizures (motor or sensory) or complex partial seizures (with motor manifestations) with or without secondarily generalized seizures
  • Subject has seizures that are distinct, stereotypical events that can be reliably counted, in the opinion of the investigator, by the subject or caregiver
  • Subject has seizures that are severe enough to cause injuries or significantly impair functional ability in domains including employment, psychosocial, education and mobility
  • Subject failed treatment with a minimum of two antiseizure medications (used in appropriate doses) with adequate monitoring of compliance and the effects of treatment
  • Subject has remained on the same antiseizure medication(s) over the preceding three (3) months (independent of dose and other than acute, intermittent use of benzodiazepines)
  • Subject has a minimum of four (4) or more countable seizures every month over the last three (3) months, as reported from the NeuroPace sponsored Prospective Seizure Frequency Clinical Investigation
  • Subject is ≥ 18 years old and ≤ 65 years old
  • Subject has undergone diagnostic testing that has established the epileptiform activity onset region(s) as part of his/her standard care to determine candidacy for epilepsy surgery
  • Subject is male, or if female is using a reliable method of contraception (hormonal, barrier method, surgical or abstention), or is at least two years postmenopause
  • Subject or legal guardian is able to provide appropriate consent to participate
  • Subject can be reasonably expected to maintain a seizure diary alone or with the assistance of a competent individual
  • Subject is able to complete regular office visits and telephone appointments per the protocol requirements
  • Subject is willing to be implanted with the RNS® System as a treatment for his/her seizures
  • Subject is able to tolerate a neurosurgical procedure
  • Subject is considered a good candidate to be implanted with an RNS® System

Note: 1 month = 28 days

Exclusion Criteria

  • Subject has been diagnosed with psychogenic or non-epileptic seizures in the preceding year
  • Subject has been diagnosed with primarily generalized seizures
  • Subject has experienced unprovoked status epilepticus in the preceding year
  • In the opinion of the investigator, the subject has a clinically significant or unstable medical condition or a progressive central nervous system disease
  • Subject has been diagnosed with active psychosis, severe depression or suicidal ideation in the preceding year
  • Subject is pregnant or planning on becoming pregnant in the next year
  • Subject is on the ketogenic diet
  • Subject was enrolled in a therapeutic investigational drug or device study in the preceding year
  • Subject has an implanted Vagus Nerve Stimulator (VNS)
  • Subject has had therapeutic surgery to treat epilepsy in the preceding year
  • Subject is implanted with an electronic medical device that delivers electrical energy to the head or body
  • Subject is on chronic anticoagulants or, in the opinion of the investigator, subject is an unsuitable candidate for cranial surgery for any other reason
  • Subject had a cranial neurosurgical procedure in the previous month
  • Subject requires repeat MRIs
  • Subject's seizure onset zone(s) is/are located below the level of the subthalamic nucleus or, in the opinion of the investigator, the necessary lead placement would present too high a risk

Note: Subjects with an inactive VNS could be enrolled so long as the VNS was explanted prior to or at the same time as the RNS® System implant. Subjects who had had epilepsy surgery (resective, corpus callosotomy or ablation) greater than one year ago were still eligible.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00079781). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search